CONTENTS
Introduction................................................................................................................................... 505
State-of-the-Art HAART Treatment.............................................................................................
506CD4 and CD8 T Lymphocytes during HIV-Induced Chronic Immune Activation...................... 507
HIV-1-Induced Apoptosis.............................................................................................................. 508
Antiretroviral Drugs and Apoptosis....................................................................................... 509
Lymphocyte Dysfunction.............................................................................................................. 510
Alternative HIV-1 Therapeutic Strategies.................................................................................... 511
Cytokines................................................................................................................................ 511
IL-2 and IL-15........................................................................................................................ 511
IL-12....................................................................................................................................... 512
IL-7......................................................................................................................................... 512
Virostatics.............................................................................................................................. 513
Hydroxyurea........................................................................................................................... 514
Mycophenolate Acid.............................................................................................................. 515
Cyclosporin............................................................................................................................ 516
Conclusion..................................................................................................................................... 516
References..................................................................................................................................... 516